Leading a pioneering approach
in antidepressant therapy

Depression is a disease that can strike anyone, at any age.
Mental health disorders can impact anyone. They are a universal concern.

0 million

people are now living
with depression worldwide,
including teenagers and children1

0%

of patients do not respond
to current treatments2

0rd

Suicide is the third leading cause
of death in 15-29 years old3

A breakthrough antidepressant redefining relief for those who need it most.

Our ambition is to develop an innovative antidepressant treatment, accessible to all, fast-acting and free from risks of dependence, sedation or psychotic effects, enabling patients to rediscover the pleasures of life and reducing the risk of suicide and relapse.

Our values : “I CARE”

“I CARE” is the core value that drives us, reflecting our desire to make a significant difference in patients’ lives.

Innovation

We dare to explore new paths to discover groundbreaking solutions.

Commitment

We’re a passionate team, working together to achieve our goals.

Ambition

We push the boundaries of science to create a lasting impact and improve patients’ quality of life.

Resilience

We learn and adapt to move forward. Seeing the opportunities when facing challenges.

Meet the team of Elkedonia

Precision medicine:
where innovation meets unique needs

We are pioneers

Elkedonia is developing a neuroplastogen with a novel target and a mechanism of action, able to induce neuroplasticity without the side effects of psychedelics

We are focusing on an innovative target, within neurons, in key brain circuits. Our approach targets intracellular events and neuroplasticity, acting on a highly selective signaling pathway

With a focus on innovation, inclusivity, and personalized medicine, Elkedonia is dedicated to advancing psychiatric treatments

They already support us

1. World Health Organization. Depression and other common mental disorders: global health estimates. Available at: https://iris.who.int/bitstream/handle/10665/254610/w?sequence=1. Accessed November 2024. Prevalence and variability of depressive symptoms in Europe: update using representative data from the second and third waves of the European Health Interview Survey (EHIS-2 and EHIS-3). Arias-de la Torre, Jorge et al. The Lancet Public Health, Volume 8, Issue 11, e889 – e898

2. The STAR*D study: Treating depression in the real world.

3. World Health Organization. Suicide fact sheet, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/suicide. Accessed November 2024.